T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells

A phase 1 study at Baylor College of Medicine (Houston, TX) found that an autologous T-cell product targeting five tumor-associated antigens was well-tolerated by patients with lymphoma both as adjuvant treatment and to treat chemorefractory disease. Among the patients with chemorefractory disease durable remissions (longer than three years) were seen in two of seven patients with HL and four of eight with NHL.